GNC Holdings Inc. will ask a US court on 17 September to approve its sale to Chinese firm Harbin Pharmaceutical Group Holding Co. Ltd. after the dietary supplement manufacturer and retailer’s bankruptcy filing received no bids competing with Harbin’s nearly $760m proposal.
GNC’s Sale Attracts No Competitors For Harbin’s Bid; Chapter 11 Bankruptcy Auction Cancelled
Deadline passed for “other qualified bidders to submit higher or otherwise better offers to purchase” full ownership of GNC. Approving sale to Harbin Pharmaceuticals, already its largest shareholder, depends partly on approval by US bankruptcy court, where a hearing is set for 17 September.

More from Deals
By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.
Direct seller has deals to fully acquire and 51% ownership of Link BioSciences, which formulates personalized supplements. It also announced a deal to acquire Pruvit Ventures, ketone supplements direct seller.
Australia's SFI Health looking to take Equazen omega-3 fatty acids supplement to new markets to capitalize on Europe's fast-growing brain health segment.
A journey began eight years ago continues for Doc Generici – now rebranded as DOC Pharma – as it continues to diversify its offerings beyond conventional generic prescription pharmaceuticals.
More from Business
Vitawell seeking to empower consumers left confused by the vast array of dietary supplements available to them in the UK.
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.